21.2 C
New York
Saturday, September 24, 2022

Buy now

spot_img

Supriya Lifescience – Guides For Double-Digit Revenue, Margin Growth In Next Two Years: HDFC Securities Initiates Coverage


BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

HDFC Securities Retail Research

Supriya Lifescience Ltd. is a well-established manufacturer and supplier of active pharmaceuticals ingredients with a focus on niche products with limited competition.

It has a niche product basket comprising 38 APIs across diverse therapeutic segments. It is the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India and is also among the largest exporters of Salbutamol Sulphate from India.

Currently, Supriya Lifescience is doing business with over 1200 plus customers and has presence in more than 86 countries.

Company has taken additional steps for business expansion around the globe especially in North America, Japan, Australia and New Zealand. Management guides for strong growth in the U.S. business over the next two-three years.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.





Source link

Related Articles

Stay Connected

0FansLike
3,497FollowersFollow
0SubscribersSubscribe
- Advertisement -spot_img

Latest Articles